Additional file 1: Supplemental Materials. of Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation Faye Norby Lindsay Bengtson Pamela Lutsey Lin Chen Richard MacLehose Alanna Chamberlain Ian Rapson Alvaro Alonso 10.6084/m9.figshare.c.3871963_D1.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Supplemental_Materials_of_Comparative_effectiveness_of_rivaroxaban_versus_warfarin_or_dabigatran_for_the_treatment_of_patients_with_non-valvular_atrial_fibrillation/5378707 Table S1. Characteristics of atrial fibrillation patients by anticoagulant use prior to final matching based on high-dimensional propensity score, MarketScan, 2010–2014. Table S2. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users (categorized by initial dose) to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S3. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing patients who switched to rivaroxaban (categorized by initial dose) from warfarin to warfarin-only users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S4. Adjusted hazard ratios (95% confidence intervals) comparing new rivaroxaban users (categorized by initial dose) to new dabigatran users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Table S5. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 36,623 patients with at least 180 days of enrolment before first oral anticoagulation prescription. Table S6. Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new warfarin users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014. Restricted to 68,927 patients with an enrolment date later than January 1st, 2011. Table S7. ICD-9-CM codes for outcomes. Table S8. ICD-9-CM codes used to define comorbidities. Figure S1. High-dimensional propensity score distribution by oral anticoagulant status for the outcome of stroke. These are the distributions prior to final matching based on high-dimensional propensity score. (DOCX 356 kb) 2017-09-06 05:00:00 Non-valvular atrial fibrillation Stroke Warfarin Dabigatran Rivaroxaban